Overview

This is the only authoritative, detailed clinical reference on Campath-1H, which stands alone among monoclonal antibodies because its reciprocal antigen CD52 is expressed in diverse cell types, and its further potential for clinical practice in hemato-oncology in the treatment of B-cell chronic lymphocytic leukemia. It records the development and actions of Campath-1H, presents the unique clinical, immunological and molecular features of B-cell chronic lymphocytic leukemia, and explores the potential of Campath-1H as frontline therapy for patients with B-CLL. The book contains five main chapters on B-cell chronic lymphocytic leukemia, the road to remission (from single agent intervention to combination therapy and onward), monoclonal antibodies in cancer (the development of Campath-1H), Campath-1H in B-CLL (remissions of refractory disease), and the role of Campath-1H prior to bone marrow transplant in refractory B-CLL plus a concluding chapter on future perspectives. Includes bibliographic references and index.

Full Product Details

9781842140604

Table of Contents

Reviews

The book gives an excellent, up-to-date, concise, comprehensive and authoritative review of the role of Campath-1H in chronic lymphocytic leukemia by leading authorities in the area. a very useful book for anyone planning to use the drug for patient treatment in the clinical setting, and also those with a wider interest in B-CLL or monoclonal antibody therapy. - By S. Mulligan, Department of Heamatology, Concord Repatriation Hospital, Concord, New South Wales, Autralia in Cancer Forum

Author Information

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available